A common theme emerging from recent antibody research is the development and validation of advanced diagnostic tools based on antibody detection. Multiple studies highlight the creation of novel biosensors and assays designed to enhance the sensitivity, specificity, and efficiency of detecting antibodies across various diseases.
For example, researchers from Universidade Federal de Viçosa introduced a magnetoelastic wave-based biosensor for the rapid and low-cost detection of antibodies against COVID-19, which demonstrated comparable diagnostic accuracy to traditional ELISA tests. In addition to being fast to execute and having the potential for automation in large-scale diagnostic studies, the biosensor fills a significant gap in existing SARS-CoV-2 detection approaches.
Another study led by Novoa et al. developed and validated a competitive inhibition ELISA for detecting antibodies against Brucella abortus in cattle, contributing to disease control in regions where brucellosis is endemic. The developed ciELISA showed significant performance, detecting the majority of vaccinated animals as negative after 135 days and could be used for the detection of anti-B. abortus antibodies in serum samples for the brucellosis control and eradication program.
Similarly, research on neutralizing antibodies for monkeypox emphasizes high-throughput methods for identifying potent candidates that could support future diagnostic and therapeutic efforts. Researchers from Guangzhou Medical University identified three potent neutralizing antibodies with the MPXV A35 protein. They found that the IC50 of MV129 was 2.68ug/mL with authentic MPXV, was the most potent antibody.
These studies reflect a broader trend toward optimizing antibody-based diagnostics, improving accessibility, and enabling quicker responses to infectious disease outbreaks.
This report aims to explore the events and trends of the biopharmaceutical industry in Q2 (April, May, June). Besides crovalimab and Vyloy, two more novel antibody drugs have been approved this year
The start of 2024 has seen leaps in deals for antibody therapeutics, especially ADCs (antibody-drug conjugates). This report aims to explore the events and trends of the biopharmaceutical industry in Q1. As of now, only two novel antibody drugs have been approved this year, but many more in regulatory review are expected to be fully approved.
Alzheimer’s research has undergone transformative changes in recent years, characterized by breakthroughs, controversies, and a reevaluation of long-held theories. Recently, BioArctic announced a global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-
The FDA has revoked Emergency Use Authorizations (EUAs) for multiple COVID-19 monoclonal antibody (mAb) therapies, including those developed by Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron. This decision reflects the challenges of targeting rapidly mutating viruses like SARS-CoV-2, which
ScientistとScience Exchangeとのご利用可能です。
